Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice

Thrombosis Research

Volumn 130, Issue 5, 2012, Pages 793-798

  Wagner, Nana Maria ^b   Dressel, Tobias ^a   Schäfer, Katrin ^a   Konstantinides, Stavros ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

arterial thrombosis; factor Xa inhibitor; photochemical injury; rivaroxaban

Indexed keywords

APOLIPOPROTEIN E; RIVAROXABAN; ROSE BENGAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; COMMON CAROTID ARTERY; DRUG EFFECT; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTICOAGULANTS; APOLIPOPROTEINS E; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FACTOR XA; FIBRINOLYTIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; THIOPHENES; THROMBOSIS;

EID: 84867573520     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.01.002     Document Type: Article

References (40)

1. Office of the Surgeon General Acting Surgeon General issues 'call to action to prevent deep vein thrombosis and pulmonary embolism September 2008 (Accessed September 1, 2011, at http://www.surgeongeneral.gov/news/ pressreleases/pr20080915.html
2. A.T. Cohen, G. Agnelli, F.A. Anderson, J.I. Arcelus, D. Bergqvist, and J.G. Brecht Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality Thromb Haemost 98 2007 756 764
3. N. Mackman Triggers, targets and treatments for thrombosis Nature 451 2008 914 918
4. M.R. Jaff, M.S. McMurtry, S.L. Archer, M. Cushman, N. Goldenberg, and S.Z. Goldhaber Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association Circulation 123 2011 1788 1830
5. A. Torbicki, A. Perrier, S.V. Konstantinides, G. Agnelli, N. Galie, and P. Pruszczyk Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 29 2008 2276 2315
6. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
7. Z.M. Ruggeri Platelets in atherothrombosis Nat Med 8 2002 1227 1234
8. R.S. Wright, J.L. Anderson, C.D. Adams, C.R. Bridges, D.E. Casey Jr., and S.M. Ettinger 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 2022 2060
9. J.I. Borissoff, H.M. Spronk, and H. ten Cate The hemostatic system as a modulator of atherosclerosis N Engl J Med 364 2011 1746 1760
10. B. Furie, and B.C. Furie Mechanisms of thrombus formation N Engl J Med 359 2008 938 949
11. J.W. Eikelboom, and J.I. Weitz New anticoagulants Circulation 121 2010 1523 1532
12. A.G. Turpie, M.R. Lassen, B.I. Eriksson, M. Gent, S.D. Berkowitz, and F. Misselwitz Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 105 2011 444 453
13. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
14. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
15. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent coronary syndrome N Engl J Med Nov 13 2011 [Epub ahead of print]
16. P.F. Bodary, and D.T. Eitzman Animal models of thrombosis Curr Opin Hematol 16 2009 342 346
17. D.T. Eitzman, R.J. Westrick, Z. Xu, J. Tyson, and D. Ginsburg Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 20 2000 1831 1834
18. S. Kikuchi, K. Umemura, K. Kondo, A.R. Saniabadi, and M. Nakashima Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimal thickening Arterioscler Thromb Vasc Biol 18 1998 1069 1078
19. S. Koschnick, S. Konstantinides, K. Schafer, K. Crain, and D.J. Loskutoff Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin J Thromb Haemost 3 2005 2290 2295
20. S. Konstantinides, K. Schäfer, T. Thinnes, and D.J. Loskutoff Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice Circulation 103 2001 576 583
21. K. Schäfer, K. Müller, A. Hecke, E. Mounier, J. Goebel, and D.J. Loskutoff Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1 Arterioscler Thromb Vasc Biol 23 2003 2097 2103
22. K. Schäfer, S. Konstantinides, C. Riedel, T. Thinnes, K. Müller, and C. Dellas Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator Circulation 106 2002 1847 1852
23. D. Gailani, N.M. Lasky, and G.J. Broze Jr. A murine model of factor XI deficiency Blood Coagul Fibrinolysis 8 1997 134 144
24. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, and F. Misselwitz The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor Nat Rev Drug Discov 10 2011 61 75
25. G.T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888
26. N. Mackman, and R.C. Becker DVT: a new era in anticoagulant therapy Arterioscler Thromb Vasc Biol 30 2010 369 371
27. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux Rivaroxaban: a new oral factor Xa inhibitor Arterioscler Thromb Vasc Biol 30 2010 376 381
28. J. Steffel, and E. Braunwald Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism Eur Heart J 32 2011 1968 1976
29. E.D. Rosen, S. Raymond, A. Zollman, F. Noria, M. Sandoval-Cooper, and A. Shulman Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi Am J Pathol 158 2001 1613 1622
30. J. Inamo, E. Belougne, and C. Doutremepuich Importance of photo activation of rose bengal for platelet activation in experimental models of photochemically induced thrombosis Thromb Res 83 1996 229 235
31. S. Konstantinides, K. Schäfer, S. Koschnick, and D.J. Loskutoff Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity J Clin Invest 108 2001 1533 1540
32. D.R. Abendschein, P.K. Baum, D.J. Martin, R. Vergona, J. Post, and G. Rumennik Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits J Cardiovasc Pharmacol 35 2000 796 805
33. J.M. Herbert, A. Bernat, F. Dol, J.P. Herault, B. Crepon, and J.C. Lormeau DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies J Pharmacol Exp Ther 276 1996 1030 1038
34. G.M. Vogel, D.G. Meuleman, F.G. Bourgondien, and P.M. Hobbelen Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans Thromb Res 54 1989 399 410
35. P.F. Bodary, R.J. Westrick, K.J. Wickenheiser, Y.C. Shen, and D.T. Eitzman Effect of leptin on arterial thrombosis following vascular injury in mice J Am Med Assoc 287 2002 1706 1709
36. D.T. Eitzman, R.J. Westrick, E.G. Nabel, and D. Ginsburg Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice Blood 95 2000 577 580
37. D.L. Brown, and P.A. Kouides Diagnosis and treatment of inherited factor X deficiency Haemophilia 14 2008 1176 1182
38. H.R. Buller, A.W. Lensing, M.H. Prins, G. Agnelli, A. Cohen, and A.S. Gallus A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study Blood 112 2008 2242 2247
39. G. Agnelli, A. Gallus, S.Z. Goldhaber, S. Haas, M.V. Huisman, and R.D. Hull Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study Circulation 116 2007 180 187
40. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and A.S. Gallus Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510